-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"Diffuse giant cell tumor of the tendon sheath is highly destructive to normal tissues and has a wide range of damag.
The ABSK021 mentioned by Associate Professor Zhou Yong is a highly selective CSF-1R small molecule inhibitor independently developed by the innovative pharmaceutical company Heyu Pharmaceutica.
It is understood that giant cell tumor of the tendon sheath is divided into localized and diffuse, with an incidence rate of about 43 per million, of which diffuse accounts for about one tenth, belonging to a rare diseas.
"Currently, surgery has reached a bottleneck in this situation," said Associate Professor Zhou Yon.
Studies have shown that overexpressed CSF1 is the main cause of giant cell tumor of the tendon sheath, and blocking the CSF1/CSF-1R pathway provides a new option for the systemic drug treatment of TGC.
"ABSK021 is currently in clinical trials, and our center has also enrolled a lot of case.
As an example, Associate Professor Zhou Yong said, "There was a patient with recurrent giant cell tumor of the tendon sheath in the knee join.
At present, there is no domestic drug for the treatment of patients with inoperable giant cell tumor of the tendon sheath, and the breakthrough therapy designation of ABSK021 is based on the excellent research results of the clinical phase Ib trial in patients with giant cell tumor of the tendon sheath, which is expected to accelerate clinical researc.
